Watson's revenue grows 25%
SAN FRANCISCO — Though it plans to announce its fiscal year 2010 results next month, Watson Pharmaceuticals offered a peak at some preliminary numbers at the 29th annual J.P. Morgan Healthcare Conference Wednesday.
Watson said that based on a review of results for last year, it expects to have earned revenues of more than $3.5 billion, a 25% increase over 2009.
“[Year] 2010 was another year of exceptional performance,” Watson CEO Paul Bisaro said. “We experienced continued solid growth across the business, with particularly strong contributions from our generic extended-release and oral contraceptive franchises in the United States, as well as from our Anda distribution business.”
The company plans to release fourth-quarter and full-year 2010 results on Feb. 15.